Akebia Therapeutics AKBA
NASDAQ AKBA
$0.92 +0.03 (+3.83%)
At close: Sep 30, 2026 · 4:00 PM EDT

Akebia Therapeutics (AKBA) Short term Debt (2018 - 2026)

Updated

Akebia Therapeutics' Short term Debt came in at $24.81 million for Q2 2026, up 98.6% from the prior quarter.

Analysis

Akebia Therapeutics (AKBA) Short term Debt (2018 - 2026) Analysis & Trends

At the end of FY2023, Akebia Therapeutics' Short term Debt was $17.5 million, down 45.3% from FY2022.

  • Short term Debt carries a five-year compound annual growth rate of 3.1% (FY2018 to FY2023).
  • Going back by year, Short term Debt was $32 million in FY2022 (-67.2%) and $97.54 million in FY2021.
  • The Q2 2026 figure represents the highest quarterly Short term Debt since Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Akebia Therapeutics 241.85 Mn -427.63 Mn 38.70 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 24.81 Mn
Mar 31, 2026 12.50 Mn
Dec 31, 2023 17.50 Mn
Sep 30, 2023 8.00 Mn
Jun 30, 2023 24.00 Mn
Mar 31, 2023 24.00 Mn
Dec 31, 2022 32.00 Mn
Sep 30, 2022 65.95 Mn
Jun 30, 2022 98.16 Mn
Mar 31, 2022 97.85 Mn
Dec 31, 2021 97.54 Mn
Dec 31, 2018 15.00 Mn
API Access

Akebia Therapeutics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=AKBA&period=max&api_key=YOUR_API_KEY